Cost-effectiveness of orlistat for the treatment of overweight and obese patients in Ireland

Lacey, Lauren; Wolf, Anne; O’Shea, Donal; Erny, Samuel; Ruof, Jörg

doi:10.1038/sj.ijo.0802947

Cited by 38 publications

(57 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Ten studies 26,157,158,[160][161][162][163][167][168][169] used obese cohorts with no comorbidities at baseline. Three studies 164,165,170 presented results for overweight cohorts with T2DM at baseline.…”

Section: Discussionmentioning

confidence: 99%

“…Two studies 159,168 assumed a linear rate of regain over a 1-year period, based on data from RIO trials that showed a 1-year period to reach baseline weight after re-randomisation to placebo following rimonabant. 115 Four studies 161,163,165,170 modelled a linear regain over a 3-year period, based on a NICE recommendation, 38 whereas one 164 assumed a 5-year period for regain. 175 …”

Section: Discussionmentioning

confidence: 99%

“…Two 161,163 included only T2DM, whereas one 166 included additional comorbidities such as osteoarthritis, low back pain and some cancers.…”

Section: Comorbidities Modelledmentioning

confidence: 99%

See 2 more Smart Citations

What is the clinical effectiveness and cost-effectiveness of using drugs in treating obese patients in primary care? A systematic review.

Ara

Blake²,

Gray³

et al. 2012

Health Technol Assess

View full text Add to dashboard Cite

How to obtain copies of this and other HTA programme reports An electronic version of this title, in Adobe Acrobat format, is available for downloading free of charge for personal use from the HTA website (www.hta.ac.uk). A fully searchable DVD is also available (see below). Printed copies of HTA journal series issues cost £20 each (post and packing free in the UK) to both public and private sector purchasers from our despatch agents. Non-UK purchasers will have to pay a small fee for post and packing. For European countries the cost is £2 per issue and for the rest of the world £3 per issue. How to order:-fax (with credit card details)-post (with credit card details or cheque)-phone during office hours (credit card only). Additionally the HTA website allows you to either print out your order or download a blank order form. Tel: 0845 812 4000-ask for 'HTA Payment Services' (out-of-hours answer-phone service) Fax: 0845 812 4001-put 'HTA Order' on the fax header Payment methods Paying by cheque If you pay by cheque, the cheque must be in pounds sterling, made payable to University of Southampton and drawn on a bank with a UK address. Paying by credit card You can order using your credit card by phone, fax or post. Subscriptions NHS libraries can subscribe free of charge. Public libraries can subscribe at a reduced cost of £100 for each volume (normally comprising 40-50 titles). The commercial subscription rate is £400 per volume (addresses within the UK) and £600 per volume (addresses outside the UK). Please see our website for details. Subscriptions can be purchased only for the current or forthcoming volume. How do I get a copy of HTA on DVD? Please use the form on the HTA website (www.hta.ac.uk/htacd/index.shtml). HTA on DVD is currently free of charge worldwide. The website also provides information about the HTA programme and lists the membership of the various committees. HTA What is the clinical effectiveness and cost-effectiveness of using drugs in treating obese patients in primary care? A systematic review set up in 1993. It produces high-quality research information on the effectiveness, costs and broader impact of health technologies for those who use, manage and provide care in the NHS. 'Health technologies' are broadly defined as all interventions used to promote health, prevent and treat disease, and improve rehabilitation and long-term care. The research findings from the HTA programme directly influence decision-making bodies such as the National Institute for Health and Clinical Excellence (NICE) and the National Screening Committee (NSC). HTA findings also help to improve the quality of clinical practice in the NHS indirectly in that they form a key component of the 'National Knowledge Service'. The HTA programme is needs led in that it fills gaps in the evidence needed by the NHS. There are three routes to the start of projects. First is the commissioned route. Suggestions for research are actively sought from people working in the NHS, from the public and consumer groups and from professional ...

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

What is the clinical effectiveness and cost-effectiveness of using drugs in treating obese patients in primary care? A systematic review.

Ara

Blake²,

Gray³

et al. 2012

Health Technol Assess

View full text Add to dashboard Cite

show abstract

“…The concept "NNT to gain 1 QALY" was used in a health economic evaluation of orlistat in the treatment of overweight patients (39). No details regarding the calculation of this estimate are given, however, and the study is based on pooled data from 5 RCTs comparing calorie-reduced diet plus orlistat or placebo.…”

Section: Discussionmentioning

confidence: 99%

Utility‐based outcomes made easy: The number needed per quality‐adjusted life year gained. An observational cohort study of tumor necrosis factor blockade in inflammatory arthritis from Southern Sweden

Gülfe¹,

Kristensen²,

Saxne³

et al. 2010

Arthritis Care & Research

View full text Add to dashboard Cite

Objective. To introduce a novel, simple, utility-based outcome measure, the number needed per quality-adjusted life year (QALY) gained (NNQ), and to apply it in clinical practice in anti-tumor necrosis factor (anti-TNF)-treated patients with rheumatoid arthritis (RA), psoriatic arthritis (PsA), and spondylarthritis (SpA). Methods. The NNQ is the number of patients one has to treat in order to gain 1 QALY. It is calculated as the inverted value of the utility gain (area under the curve) over 1 year in a cohort subjected to an intervention. EuroQol Index utility data from the South Swedish Arthritis Treatment register were used.

show abstract

“…It is not clear what proportion of this reduction is due to the effects of diet versus medication use but a reduction of this magnitude, if achieved, is sufficient to significantly decrease mortality and the risk of developing cardiovascular disease or cancer [8]. Some studies have shown that anti-obesity medications are a cost-effective form of treatment [9,10], however, the research is often funded by pharmaceutical companies and relies on large assumptions [11]. Despite the potential benefits of using anti-obesity medication a history of safety fears and a variety of side effects may have hampered their use [5,12].…”

Section: Introductionmentioning

confidence: 99%

Factors Related to Successful Weight Reduction among Subjects who Tried to Reduce Their Weight for 1 Year: Data from the 2015 Korea National Health and Nutrition Examination Survey

Jung¹,

Jeong²

2017

J Health Info Stat

View full text Add to dashboard Cite

show abstract

Cost-effectiveness of orlistat for the treatment of overweight and obese patients in Ireland

Abstract: Our model suggests that orlistat is effective and cost-effective in obese patients, if after 3 months of treatment, only treatment responders continue treatment.

Cited by 38 publications

References 29 publications

What is the clinical effectiveness and cost-effectiveness of using drugs in treating obese patients in primary care? A systematic review.

What is the clinical effectiveness and cost-effectiveness of using drugs in treating obese patients in primary care? A systematic review.

Utility‐based outcomes made easy: The number needed per quality‐adjusted life year gained. An observational cohort study of tumor necrosis factor blockade in inflammatory arthritis from Southern Sweden

Factors Related to Successful Weight Reduction among Subjects who Tried to Reduce Their Weight for 1 Year: Data from the 2015 Korea National Health and Nutrition Examination Survey

Contact Info

Product

Resources

About